Polymyalgia Rheumatica Market 2025: In-Depth Analysis of Size, Share & Forecast

30 Apr, 2025

The Polymyalgia Rheumatica Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.

What are the Historical Growth Trends in the Polymyalgia Rheumatica Market?

The market for polymyalgia rheumatica has recently expanded considerably. The market, valued at $1.28 billion in 2024, is projected to increase to $1.36 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%.

What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Polymyalgia Rheumatica Industry?

In 2029, the polymyalgia rheumatica market is projected to reach $1.73 billion, growing at a compound annual growth rate (CAGR) of 6.2%.

Download Your Free Sample of the 2025 Polymyalgia Rheumatica Market Report and Uncover Key Trends Now!

What are the Key Growth Drivers Fueling the Polymyalgia Rheumatica Market?

The key drivers in the polymyalgia rheumatica market are:

• Increasing adoption of biologics in treatment
• The expansion of precision medicine
• Accelerated drug approvals by regulatory bodies
• Expansion of clinical trials in the field.

Global Market Segmentation: Identifying Major Polymyalgia Rheumatica Industry Segments

The polymyalgia rheumatica market covered in this report is segmented –
1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Type: Adult, Geriatric, Periatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Pre-order the 2025 Polymyalgia Rheumatica Global Market Report for Fast Delivery & Comprehensive Insights!

What are the emerging Trends Shaping the Future of the Polymyalgia Rheumatica Market?

The key trends in the polymyalgia rheumatica market are:

• The adoption of biologics is a growing trend in the polymyalgia rheumatica market.
• Advancements in personalized medicine and precision medicine are also emerging trends.
• The integration of electronic health records is increasingly influencing the market.
• Additionally, advancements in biomarkers are shaping the future.

Who Are the Top Competitors & Leading Players in the Polymyalgia Rheumatica Market?

Major players in the polymyalgia rheumatica market are:

• AbbVie Inc.
• Sanofi S.A.
• Eli Lilly and Co.
• Regeneron Pharmaceuticals Inc.
• Mount Sinai
• NYU Langone Health
• Mayo Foundation for Medical Education and Research
• Hartford HealthCare
• Horizon Therapeutics plc
• Massachusetts General Hospital
• Brigham and Women's Hospital
• Stanford Health Care
• University Hospitals Bristol NHS Foundation Trust
• Circle Health Group Ltd.
• Siloam Hospital
• UC San Diego Health
• Vejthani Hospital
• Sparrow Pharmaceuticals Inc.
• Johns Hopkins Arthritis Center
• Upstate University Hospital

Regional Dominance: Which Area Leads the Global Template Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024